Circassia Group PLC
LSE:CIR
| US |
|
Johnson & Johnson
NYSE:JNJ
|
Pharmaceuticals
|
| US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
Financial Services
|
| US |
|
Bank of America Corp
NYSE:BAC
|
Banking
|
| US |
|
Mastercard Inc
NYSE:MA
|
Technology
|
| US |
|
UnitedHealth Group Inc
NYSE:UNH
|
Health Care
|
| US |
|
Exxon Mobil Corp
NYSE:XOM
|
Energy
|
| US |
|
Pfizer Inc
NYSE:PFE
|
Pharmaceuticals
|
| US |
|
Palantir Technologies Inc
NYSE:PLTR
|
Technology
|
| US |
|
Nike Inc
NYSE:NKE
|
Textiles, Apparel & Luxury Goods
|
| US |
|
Visa Inc
NYSE:V
|
Technology
|
| CN |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
Retail
|
| US |
|
JPMorgan Chase & Co
NYSE:JPM
|
Banking
|
| US |
|
Coca-Cola Co
NYSE:KO
|
Beverages
|
| US |
|
Walmart Inc
NYSE:WMT
|
Retail
|
| US |
|
Verizon Communications Inc
NYSE:VZ
|
Telecommunication
|
| US |
|
Chevron Corp
NYSE:CVX
|
Energy
|
Utilize notes to systematically review your investment decisions. By reflecting on past outcomes, you can discern effective strategies and identify those that underperformed. This continuous feedback loop enables you to adapt and refine your approach, optimizing for future success.
Each note serves as a learning point, offering insights into your decision-making processes. Over time, you'll accumulate a personalized database of knowledge, enhancing your ability to make informed decisions quickly and effectively.
With a comprehensive record of your investment history at your fingertips, you can compare current opportunities against past experiences. This not only bolsters your confidence but also ensures that each decision is grounded in a well-documented rationale.
Do you really want to delete this note?
This action cannot be undone.
| 52 Week Range |
N/A
N/A
|
| Price Target |
|
We'll email you a reminder when the closing price reaches GBX.
Choose the stock you wish to monitor with a price alert.
|
Johnson & Johnson
NYSE:JNJ
|
US |
|
Berkshire Hathaway Inc
NYSE:BRK.A
|
US |
|
Bank of America Corp
NYSE:BAC
|
US |
|
Mastercard Inc
NYSE:MA
|
US |
|
UnitedHealth Group Inc
NYSE:UNH
|
US |
|
Exxon Mobil Corp
NYSE:XOM
|
US |
|
Pfizer Inc
NYSE:PFE
|
US |
|
Palantir Technologies Inc
NYSE:PLTR
|
US |
|
Nike Inc
NYSE:NKE
|
US |
|
Visa Inc
NYSE:V
|
US |
|
Alibaba Group Holding Ltd
NYSE:BABA
|
CN |
|
JPMorgan Chase & Co
NYSE:JPM
|
US |
|
Coca-Cola Co
NYSE:KO
|
US |
|
Walmart Inc
NYSE:WMT
|
US |
|
Verizon Communications Inc
NYSE:VZ
|
US |
|
Chevron Corp
NYSE:CVX
|
US |
This alert will be permanently deleted.
Circassia Group PLC
Net Income (Common)
Circassia Group PLC
Net Income (Common) Peer Comparison
Competitors Analysis
Latest Figures & CAGR of Competitors
| Company | Net Income (Common) | CAGR 3Y | CAGR 5Y | CAGR 10Y | ||
|---|---|---|---|---|---|---|
|
Circassia Group PLC
LSE:CIR
|
Net Income (Common)
ÂŁ16.1m
|
CAGR 3-Years
N/A
|
CAGR 5-Years
N/A
|
CAGR 10-Years
N/A
|
|
|
Centessa Pharmaceuticals PLC
NASDAQ:CNTA
|
Net Income (Common)
-$235.8m
|
CAGR 3-Years
15%
|
CAGR 5-Years
-116%
|
CAGR 10-Years
N/A
|
|
|
Autolus Therapeutics PLC
NASDAQ:AUTL
|
Net Income (Common)
-$224.8m
|
CAGR 3-Years
-11%
|
CAGR 5-Years
-10%
|
CAGR 10-Years
N/A
|
|
|
Immunocore Holdings PLC
NASDAQ:IMCR
|
Net Income (Common)
-ÂŁ51.1m
|
CAGR 3-Years
27%
|
CAGR 5-Years
13%
|
CAGR 10-Years
N/A
|
|
|
Genus PLC
LSE:GNS
|
Net Income (Common)
ÂŁ19.3m
|
CAGR 3-Years
-22%
|
CAGR 5-Years
-11%
|
CAGR 10-Years
-7%
|
|
|
Oxford BioMedica PLC
LSE:OXB
|
Net Income (Common)
-ÂŁ37.1m
|
CAGR 3-Years
-15%
|
CAGR 5-Years
-24%
|
CAGR 10-Years
-14%
|
|
Circassia Group PLC
Glance View
Circassia Group Plc is a holding company, which engages in the development and commercialization of respiratory products. The company is headquartered in Oxford, Oxfordshire and currently employs 128 full-time employees. The company went IPO on 2014-03-13. The firm operates through two segments: NIOX and COPD. The NIOX segment relates to the portfolio of products used to improve asthma diagnosis and management by measuring fractional exhaled nitric oxide (FeNO). The COPD segment relates to the Tudorza and Duaklir Pressair products marketed in the United States, where they are indicated for the maintenance treatment of patients with COPD. Its NIOX FeNO measurement and monitoring products are used by physicians around the world to help improve asthma diagnosis and management. Its FeNO diagnosis and management products helps healthcare to professionals manage their patient's asthma. Its NIOX VERO is a non-invasive, point-of-care system that provides FeNO measurements. The firm provides products and services in around 50 countries.
See Also
What is Circassia Group PLC's Net Income (Common)?
Net Income (Common)
16.1m
GBP
Based on the financial report for Dec 31, 2022, Circassia Group PLC's Net Income (Common) amounts to 16.1m GBP.
What is Circassia Group PLC's Net Income (Common) growth rate?
Net Income (Common) CAGR 1Y
347%
Over the last year, the Net Income (Common) growth was 347%.